WatchGov

119th Congress

H.R. 1492

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

  1. Introduced
  2. In committee
  3. Passed House
  4. Passed Senate
  5. To President
  6. Became law
Sponsor
Gregory F. Murphy(R-NC)
Introduced
Feb 21, 2025
Policy area
Health
Committees
House Committee on Energy and Commerce; House Committee on Ways and Means
Official text
Introduced in House · Congress.gov page

Cosponsors (68)

Original cosponsors (2)

Added later (66)

Summary

Summary by the Congressional Research Service· describes the “Introduced in House” version

This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program. The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation. The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation. The bill's changes apply retroactively.

Roll-call votes

No recorded votes on this bill.

Actions